PT  - JOURNAL ARTICLE
AU  - Nigro, Olga
AU  - Pinotti, Graziella
AU  - De Galitiis, Federica
AU  - Di Pietro, Francesca Romana
AU  - Giusti, Raffaele
AU  - Filetti, Marco
AU  - Bersanelli, Melissa
AU  - Lazzarin, Alessandro
AU  - Bordi, Paola
AU  - Catino, Annamaria
AU  - Pizzutilo, Pamela
AU  - Galetta, Domenico
AU  - Marchetti, Paolo
AU  - Botticelli, Andrea
AU  - Scagnoli, Simone
AU  - Russano, Marco
AU  - Santini, Daniele
AU  - Torniai, Mariangela
AU  - Berardi, Rossana
AU  - Ricciuti, Biagio
AU  - De Giglio, Andrea
AU  - Chiari, Rita
AU  - Russo, Alessandro
AU  - Adamo, Vincenzo
AU  - Tudini, Marianna
AU  - Silva, Rosa Rita
AU  - Bolzacchini, Elena
AU  - Giordano, Monica
AU  - Di Marino, Pietro
AU  - De Tursi, Michele
AU  - Rijavec, Erika
AU  - Ghidini, Michele
AU  - Vallini, Ilaria
AU  - Stucci, Luigia Stefania
AU  - Tucci, Marco
AU  - Pala, Laura
AU  - Conforti, Fabio
AU  - Queirolo, Paola
AU  - Tanda, Enrica
AU  - Spagnolo, Francesco
AU  - Cecchi, Federica
AU  - Bracarda, Sergio
AU  - Macrini, Serena
AU  - Santoni, Matteo
AU  - Battelli, Nicola
AU  - Fargnoli, Maria Concetta
AU  - Porzio, Giampiero
AU  - Tuzi, Alessandro
AU  - Suter, Matteo Basilio
AU  - Ficorella, Corrado
AU  - Cortellini, Alessio
TI  - Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study
AID  - 10.1101/2020.04.09.20054031
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.09.20054031
4099  - http://medrxiv.org/content/early/2020/04/14/2020.04.09.20054031.short
4100  - http://medrxiv.org/content/early/2020/04/14/2020.04.09.20054031.full
AB  - Data on spectrum and grade of immune-related adverse events (irAEs) in long-term responders to immune checkpoint inhibitors (ICI) are lacking.We performed a retrospective multicenter study to characterized irAEs occurring after a 12-months minimum treatment period with PD-(L)1 ICIs in advanced cancer patients. IrAEs were categorized into “early” (≤12 months) and “late” (>12 months).From September 2013 to October 2019, 436 consecutive patients were evaluated. 223 experienced any grade early-irAEs (51.1%), while 132 experienced any grade late-irAEs (30.3%) (p < 0.0001). Among the latter, 29 (22%) experienced a recurrence of an early-irAEs, while 103 (78%) experienced de novo late-irAEs involving different system/organ. Among patients with late-irAEs, 21 experienced G3/G4 irAEs (4.8%). Median time to onset of early-irAEs was 3.4 months (95%CI: 2.8-4.2), while the median time to onset of late-irAEs was 16.6 months (95%CI: 15.8-17.6). Cumulative time-adjusted risk of disease progression according to both the early-irAEs (HR = 0.63 [95%CI: 0.30-1.29], p = 0.204) and late-irAEs occurrence revealed no statistically significant differences (HR = 0.75 [95%CI: 0.37-1.56], p = 0.452). Also the time-adjusted cumulative risk of death according to both early-irAEs (HR = 0.79 [95%CI: 0.34-1.86], p = 0.598) and late-irAEs (HR = 0.92 [95%CI: 0.49-1.74], p = 0.811) did not show statistically significant differences.Although less frequent than early-irAEs, late-irAEs are quite common in long responders to PD-(L)1 ICIs, and are different in terms of spectrum and grade. Time-adjusted analysis revealed that the cumulative risk of disease progression and death were not significantly reduced in patients who experienced late-irAEs.Competing Interest StatementDr. Alessio Cortellini received grants as speaker by MSD and Astra-Zeneca; grant consultancies by BMS, Roche, Novartis, Istituto Gentili and Ipsen. Dr. Melissa Bersanelli received research funding by Roche, Pfizer, Seqirus, AstraZeneca, Bristol-Myers Squibb, Novartis and Sanofi; she also received honoraria for advisory role and as speaker at scientific events by Bristol-Myers Squibb, Novartis and Pfizer. Dr. Marco Russano received honoraria for scientific events by Roche, Astrazeneca, Bristol-Myers Squibb, Merck Sharp & Dohme and Boehringer Ingelheim. Dr. Raffaele Giusti Advisory Boards/ Honoraria/ Speakers’ fee/ Consultant for: Astra Zeneca, Roche.Funding StatementNo funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesthe datasets used during the present study are available from the corresponding author upon reasonable request